Ballantyne, Christie M.

Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis

Khan, S. U., Lone, A. N., Khan, M. S., Virani, S. S., Blumenthal, R. S., Nasir, K., Miller, M., Michos, E. D., Ballantyne, C. M., Boden, W. E., et al. (2021) · eClinicalMedicine

Fatty Acid Research and HealthNutritional Studies and Diet

Cited by 411

Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study

Davidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics

Lipoproteins and Cardiovascular HealthFatty Acid Research and Health

Cited by 385

Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)

Bays, H. E., Ballantyne, C. M., Kastelein, J. J., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2011) · The American Journal of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 358

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy

Ballantyne, C. M., Laufs, U., Ray, K. K., Leiter, L. A., Bays, H. E., Goldberg, A. C., Stroes, E. S., MacDougall, D., Zhao, X., & Catapano, A. L. (2020) · European Journal of Preventive Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 358

Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)

Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2012) · The American Journal of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 342

2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia

Virani, S. S., Morris, P. B., Agarwala, A., Ballantyne, C. M., Birtcher, K. K., Kris-Etherton, P. M., Ladden-Stirling, A. B., Miller, M., Orringer, C. E., & Stone, N. J. (2021) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 341

Development and validation of a patient self-assessment score for diabetes risk

Bang, H., Edwards, A. M., Bomback, A. S., Ballantyne, C. M., Brillon, D., Callahan, M. A., Teutsch, S. M., Mushlin, A. I., & Kern, L. M. (2009) · Annals of Internal Medicine

Health Promotion and Cardiovascular PreventionDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 333

Plasma Lipid Profile and Incident Ischemic Stroke: The Atherosclerosis Risk in Communities (ARIC) Study

Shahar, E., Chambless, L. E., Rosamond, W. D., Boland, L. L., Ballantyne, C. M., McGovern, P. G., & Sharrett, A. R. (2003) · Stroke

Lipoproteins and Cardiovascular HealthAcute Ischemic Stroke Management

Cited by 325

Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients

Morrisett, J. D., Abdel-Fattah, G., Hoogeveen, R., Mitchell, E., Ballantyne, C. M., Pownall, H. J., Opekun, A. R., Jaffe, J. S., Oppermann, S., & Kahan, B. D. (2002) · Journal of Lipid Research

Renal Transplantation Outcomes and TreatmentsLipoproteins and Cardiovascular Health

Cited by 295

Ten things to know about ten cardiovascular disease risk factors

Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology

Cardiovascular Health and Risk FactorsHealth Promotion and Cardiovascular Prevention

Cited by 274

Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome

Stroes, E. S. G., Alexander, V. J., Karwatowska-Prokopczuk, E., Hegele, R. A., Arca, M., Ballantyne, C. M., Soran, H., Prohaska, T. A., Xia, S., Ginsberg, H. N., et al. (2024) · New England Journal of Medicine

Lipid metabolism and disordersPancreatitis Pathology and Treatment

Cited by 271

Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group Recommendations

Davidson, M. H., Maki, K. C., Pearson, T. A., Pasternak, R. C., Deedwania, P. C., McKenney, J. M., Fonarow, G. C., Maron, D. J., Ansell, B. J., Clark, L. T., et al. (2005) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthHealth Promotion and Cardiovascular Prevention

Cited by 270

Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists

Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 262

Effects of Icosapent Ethyl on Total Ischemic Events

Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · Journal of the American College of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 259

Obesity and subtypes of incident cardiovascular disease

Ndumele, C. E., Matsushita, K., Lazo, M., Bello, N., Blumenthal, R. S., Gerstenblith, G., Nambi, V., Ballantyne, C. M., Solomon, S. D., Selvin, E., et al. (2016) · Journal of the American Heart Association

Cardiovascular Function and Risk FactorsDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 259

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial

Tardif, J.-C., Ballantyne, C. M., Barter, P., Dasseux, J.-L., Fayad, Z. A., Guertin, M.-C., Kastelein, J. J. P., Keyserling, C., Klepp, H., Koenig, W., et al. (2014) · European Heart Journal

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 251

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Gouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., Hughes, S. G., Gaudet, D., Hegele, R. A., O'Dea, L. S. L., et al. (2021) · The Lancet Diabetes & Endocrinology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 232

Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia

Rosenson, R. S., Gaudet, D., Hegele, R. A., Ballantyne, C. M., Nicholls, S. J., Lucas, K. J., San Martin, J., Zhou, R., Muhsin, M., Chang, T., et al. (2024) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 213

Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque

the CARDIoGRAM Consortium, Bis, J. C., Kavousi, M., Franceschini, N., Isaacs, A., Abecasis, G. R., Schminke, U., Post, W. S., Smith, A. V., Cupples, L. A., et al. (2011) · Nature Genetics

Genetic Associations and EpidemiologyCardiovascular Health and Disease Prevention

Cited by 212

Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk

Walker, K. A., Chen, J., Zhang, J., Fornage, M., Yang, Y., Zhou, L., Grams, M. E., Tin, A., Daya, N., Hoogeveen, R. C., et al. (2021) · Nature Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 212

Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia

Ballantyne, C. M., Vasas, S., Azizad, M., Clifton, P., Rosenson, R. S., Chang, T., Melquist, S., Zhou, R., Mushin, M., Leeper, N. J., et al. (2024) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 210

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

Tardif, J.-C., Karwatowska-Prokopczuk, E., Amour, E. S., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Hurh, E., Bartlett, V. J., Kingsbury, J., et al. (2022) · European Heart Journal

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 210

Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia

Ballantyne, C. M., Blazing, M. A., King, T. R., Brady, W. E., & Palmisano, J. (2004) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 202

Racial differences in glycemic markers: a cross-sectional analysis of community-based data

Selvin, E., Steffes, M. W., Ballantyne, C. M., Hoogeveen, R. C., Coresh, J., & Brancati, F. L. (2011) · Annals of Internal Medicine

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 196